1. Home
  2. HL vs CYTK Comparison

HL vs CYTK Comparison

Compare HL & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hecla Mining Company

HL

Hecla Mining Company

N/A

Current Price

$15.46

Market Cap

11.3B

ML Signal

N/A

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

N/A

Current Price

$55.53

Market Cap

10.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HL
CYTK
Founded
1891
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.3B
10.7B
IPO Year
2002
2004

Fundamental Metrics

Financial Performance
Metric
HL
CYTK
Price
$15.46
$55.53
Analyst Decision
Buy
Buy
Analyst Count
10
21
Target Price
$21.68
★ $107.39
AVG Volume (30 Days)
★ 28.8M
1.8M
Earning Date
11-03-2026
11-04-2026
Dividend Yield
★ 0.10%
N/A
EPS Growth
★ 716.67
N/A
EPS
★ 0.37
N/A
Revenue
★ $645,957,000.00
$13,368,000.00
Revenue This Year
N/A
$88.01
Revenue Next Year
$20.85
$171.26
P/E Ratio
$39.66
★ N/A
Revenue Growth
★ 45.63
N/A
52 Week Low
$12.80
$53.96
52 Week High
$34.17
$88.31

Technical Indicators

Market Signals
Indicator
HL
CYTK
Relative Strength Index (RSI) 51.28 33.37
Support Level $14.20 N/A
Resistance Level $16.43 $66.93
Average True Range (ATR) 0.63 2.42
MACD 0.22 -0.51
Stochastic Oscillator 94.63 16.82

Price Performance

Historical Comparison
HL
CYTK

About HL Hecla Mining Company

Hecla Mining Co produces and explores silver, gold, zinc, and other metals. The operating business segments are Greens Creek, Lucky Friday, Keno Hill, and Casa Berardi. It generates maximum revenue from the Greens Creek segment. Geographically, It operates in Canada, the United States, and Mexico, and it derives a majority of its revenue from the United States.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: